What Happens When Tirzepatide Is Stopped? What SURMOUNT-4 Showed
SURMOUNT-4 is one of the most commercially important obesity trials because it addresses the question patients actually ask in clinic: if I stop tirzepatide, what then? After a 36‑week open-label lead-in, participants had already lost a large amount of weight on tirzepatide. They were then randomised either to continue treatment or switch to placebo. By week 88, overall mean weight reduction from baseline was 25.3% with continued tirzepatide and 9.9% with placebo, reflecting substantial regain after withdrawal.[1]
That does not mean tirzepatide is a trick. It means the underlying disease process does not retire simply because the scales improved for a while.
The trial showed three things. Continued tirzepatide maintained and augmented the initial response. Withdrawal led to regain. And much of the early cardiometabolic improvement began to reverse when weight returned.[1][2] That last point is the one many summaries underplay. Regain is not merely disappointing. It may carry metabolic consequences.
Like STEP 4, this was a withdrawal design. That makes it more clinically relevant than an abstract efficacy contest. Patients do not arrive as blank slates; many arrive after months of treatment, wondering whether the next phase can be made cheaper, lighter or drug-free. SURMOUNT‑4 tells you that stopping potent pharmacotherapy after a strong response is not a neutral act. It changes the physiological landscape.
What most articles miss is that the trial does not prove every patient must stay on tirzepatide indefinitely. It shows that, on average, abrupt withdrawal is associated with regain.[1] It does not test a bespoke taper, resistance-training-heavy maintenance phase, or a structured appetite-management protocol. It therefore demonstrates the risk more convincingly than the best off-ramp. The people entering randomisation were those who had tolerated and responded to treatment, so the evidence applies best to that group.
For the patient considering exit, SURMOUNT‑4 supports a staged rather than casual approach. That means deciding in advance what you are trying to preserve: not just body weight, but appetite control, body composition, waist, blood pressure, glycaemic drift, movement tolerance and confidence around food. It also supports early follow-up after dose reduction. The dangerous period is not merely the day the prescription ends. It is the weeks afterwards, when food noise returns, rules loosen, compensatory eating creeps in and muscle mass is too often neglected.
When to involve your clinician: before stopping, if appetite returns rapidly, if blood pressure or glucose control drifts, or if intake and hydration become inconsistent.
When to seek urgent help: severe abdominal pain, persistent vomiting, dehydration, suspected gallbladder disease, pancreatitis symptoms or hypersensitivity reactions.[2]
Bottom line: SURMOUNT‑4 is not an argument for hopeless dependence. It is an argument against naive withdrawal. The real clinical challenge is not inducing weight loss. It is designing what happens next.[1][2]
FAQs
-
Participants switched to placebo regained a substantial portion of the weight lost during the lead-in; by week 88 total mean loss from baseline was 9.9% in the placebo group versus 25.3% with continued tirzepatide.[1]
-
No. It means that stopping without a maintenance framework carries a real risk of regain and metabolic reversal.[1]
-
Yes. The trial discussion notes reversal of much of the initial cardiometabolic improvement in the withdrawal group.[1]
-
No. It was a randomised withdrawal trial, which is an important limitation when patients ask about individualised off-ramp strategies.[1]
-
If you plan to stop tirzepatide, do not improvise. Maintenance needs structure, monitoring and a defined fallback plan.
References
1. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936
2. Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
3. Horn DB, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2025. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2841273
